Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 envelope glycoprotein gp160 is a crucial viral protein synthesized as a precursor in the rough endoplasmic reticulum of infected host cells. It oligomerizes into trimers and is subsequently cleaved by host cell furin-like proteases in the Golgi apparatus into two non-covalently associated subunits: the surface subunit gp120 and the transmembrane subunit gp41. Together, these subunits form the mature envelope spike on the virion surface, which is essential for viral entry. The gp120 subunit mediates initial attachment to the host CD4 receptor and chemokine co-receptors (CCR5 or CXCR4), while gp41 facilitates the subsequent fusion of the viral and host cell membranes. Truncated variants, such as gp150, are engineered by removing the cytoplasmic tail to enhance surface expression and stability, making them valuable tools in vaccine design and structural studies.
As the sole viral antigen exposed on the surface of HIV-1 virions, gp160 is a primary target for both therapeutic interventions and vaccine development. Antiretroviral drugs target different subunits of gp160 to block viral entry; for example, fostemsavir (and its active form temsavir) acts as an attachment inhibitor by binding to gp120, while enfuvirtide and albuvirtide act as fusion inhibitors by binding to gp41. Additionally, gp160 is the target of broadly neutralizing antibodies (bnAbs) such as VRC01, 3BNC117, and 10-1074, which are being evaluated in clinical trials for passive immunization and viral suppression. However, the high mutation rate of HIV-1 leads to rapid conformational changes and glycan shielding, presenting significant challenges for vaccine efficacy and the development of drug resistance.
Inhibition of viral attachment to host CD4 receptors (e.g., by binding to the gp120 subunit) or inhibition of viral-host membrane fusion (e.g., by binding to the gp41 subunit).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Envelope glycoprotein gp160 (gp160).